ImpediMed Achieves Record Revenue and Strengthens Sales Leadership

Impedimed Limited ( (AU:IPD) ) just unveiled an announcement.

ImpediMed Limited reported a record revenue of A$3.4 million for the third quarter of FY25, alongside a significant increase in annual recurring revenue and total contracted value. The company appointed Scott Long as the new SVP of Sales, aiming to enhance sales operations and market penetration. Despite a decrease in total SOZO unit sales, the company saw a 10% increase in US sales and maintained low churn rates. ImpediMed is focusing on converting leads into sales, supported by increased media activity and conference participation. The company ended the quarter with a cash balance of A$27.9 million, bolstered by a growth capital facility drawdown.

More about Impedimed Limited

ImpediMed Limited is a company operating in the medical device industry, focusing on products that aid in the detection and management of lymphoedema, particularly through its SOZO device. The company is committed to advancing its market presence through strategic sales initiatives and partnerships, primarily targeting healthcare providers and institutions involved in cancer treatment and management.

YTD Price Performance: -17.50%

Average Trading Volume: 78,475

Technical Sentiment Signal: Buy

Current Market Cap: $46.92M

Learn more about IPD stock on TipRanks’ Stock Analysis page.